Shinji Ohno
#164,223
Most Influential Person Now
Researcher
Shinji Ohno's AcademicInfluence.com Rankings
Shinji Ohnocomputer-science Degrees
Computer Science
#9709
World Rank
#10186
Historical Rank
Computational Linguistics
#2381
World Rank
#2404
Historical Rank
Machine Learning
#4323
World Rank
#4372
Historical Rank
Artificial Intelligence
#4675
World Rank
#4737
Historical Rank
Download Badge
Computer Science
Shinji Ohno's Degrees
- PhD Computer Science University of Tokyo
- Masters Computer Science University of Tokyo
- Bachelors Computer Science University of Tokyo
Similar Degrees You Can Earn
Why Is Shinji Ohno Influential?
(Suggest an Edit or Addition)Shinji Ohno's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2015) (1411)
- Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy (2017) (958)
- Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2019) (917)
- 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)† (2018) (820)
- 3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). (2017) (661)
- 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) (529)
- Breast lesions: correlation of contrast medium enhancement patterns on MR images with histopathologic findings and tumor angiogenesis. (1996) (467)
- 3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3) (2017) (405)
- Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer (2004) (228)
- Measles virus: cellular receptors, tropism and pathogenesis. (2006) (227)
- 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). (2016) (208)
- Activation of PI3K/Akt signaling and hormone resistance in breast cancer (2006) (200)
- Overexpression of the MTA1 gene in gastrointestinal carcinomas: Correlation with invasion and metastasis (1997) (175)
- Genetic evidence linking SAP, the X-linked lymphoproliferative gene product, to Src-related kinase FynT in T(H)2 cytokine regulation. (2004) (147)
- Pathologic features of superficial esophageal squamous cell carcinoma with lymph node and distal metastasis (2002) (146)
- Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer (2010) (127)
- Multiple occurrence of carcinoma in the upper aerodigestive tract associated with esophageal cancer: Reference to smoking, drinking and family history (1994) (127)
- The association between Akt activation and resistance to hormone therapy in metastatic breast cancer. (2006) (120)
- Microvessel quantification and its possible relation with liver metastasis in colorectal cancer (1996) (117)
- Long Untranslated Regions of the Measles Virus M and F Genes Control Virus Replication and Cytopathogenicity (2005) (117)
- Phyllodes tumor of the breast: correlation between MR findings and histologic grade. (2006) (115)
- Dissection of measles virus V protein in relation to its ability to block alpha/beta interferon signal transduction. (2004) (113)
- Clinical significance of the 21‐gene signature (Oncotype DX) in hormone receptor‐positive early stage primary breast cancer in the Japanese population (2010) (111)
- The 3' enhancer CNS2 is a critical regulator of interleukin-4-mediated humoral immunity in follicular helper T cells. (2012) (108)
- The 3' enhancer CNS2 is a critical regulator of interleukin-4-mediated humoral immunity in follicular helper T cells. (2012) (108)
- Measles Virus Infects both Polarized Epithelial and Immune Cells by Using Distinctive Receptor-Binding Sites on Its Hemagglutinin (2008) (107)
- Both RIG-I and MDA5 RNA Helicases Contribute to the Induction of Alpha/Beta Interferon in Measles Virus-Infected Human Cells (2009) (106)
- Measles Virus Circumvents the Host Interferon Response by Different Actions of the C and V Proteins (2008) (105)
- Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2019) (105)
- Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival (2008) (100)
- Serial histologic evaluation of multiple primary squamous cell carcinomas of the esophagus (1988) (94)
- Lugol‐combined Endoscopie Detection of Minute Malignant Lesions of the Thoracic Esophagus (1988) (93)
- Measles virus receptors. (2009) (92)
- F-box protein FBXW7 inhibits cancer metastasis in a non-cell-autonomous manner. (2015) (91)
- A Human Lung Carcinoma Cell Line Supports Efficient Measles Virus Growth and Syncytium Formation via a SLAM- and CD46-Independent Mechanism (2007) (88)
- 3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3) (2016) (88)
- Clinicopathologic study of early stage esophageal carcinoma (1989) (86)
- Translational Inhibition and Increased Interferon Induction in Cells Infected with C Protein-Deficient Measles Virus (2006) (85)
- Prognostic and predictive value of epidermal growth factor receptor in recurrent breast cancer. (2002) (83)
- p53 polymorphism in human papillomavirus-associated esophageal cancer. (2000) (82)
- Clinicopathologic characteristics and outcome of adenocarcinoma of the human gastric cardia in comparison with carcinoma of other regions of the stomach. (1995) (82)
- Y-box binding protein-1 (YB-1) promotes cell cycle progression through CDC6-dependent pathway in human cancer cells. (2010) (80)
- Patterns of peripheral enhancement in breast masses: correlation of findings on contrast medium enhanced MRI with histologic features and tumor angiogenesis. (1997) (79)
- Prognostic value of c‐erbB2 expression in breast cancer (2002) (78)
- Probiotic Beverage with Soy Isoflavone Consumption for Breast Cancer Prevention: A Case-control Study (2013) (78)
- Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2019) (72)
- The exon/intron organization and chromosomal mapping of the mouse ADAMTS-1 gene encoding an ADAM family protein with TSP motifs. (1997) (68)
- Immunohistochemical evaluation of squamous cell carcinoma antigen and s‐100 protein‐positive cells in human malignant esophageal tissues (1990) (67)
- Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: results from a double-blind, phase II comparative study (FINDER1). (2010) (67)
- Prevention of adenocarcinoma colon 26-induced cachexia by interleukin 10 gene transfer. (1997) (65)
- Unmet Information Needs and Quality of Life in Young Breast Cancer Survivors in Japan (2015) (64)
- Measles Virus Infection of SLAM (CD150) Knockin Mice Reproduces Tropism and Immunosuppression in Human Infection (2006) (61)
- Trisaccharide containing α2,3-linked sialic acid is a receptor for mumps virus (2016) (61)
- Lymphatic invasion and potential for tumor growth and metastasis in patients with gastric cancer. (1995) (60)
- Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2 (2013) (60)
- Diminished expression of ING1 mRNA and the correlation with p53 expression in breast cancers. (2000) (60)
- Thermal enhancement of drug uptake and DNA adducts as a possible mechanism for the effect of sequencing hyperthermia on cisplatin-induced cytotoxicity in L1210 cells (1994) (59)
- Grb7 signal transduction protein mediates metastatic progression of esophageal carcinoma (2000) (58)
- Tumor angiogenesis and micrometastasis in bone marrow of patients with early gastric cancer. (1998) (58)
- Research needs in breast cancer (2016) (57)
- Cytokeratin-positive cells in bone marrow for identifying distant micrometastasis of gastric cancer. (1996) (56)
- Identification of molecular markers for metastasis-related genes in primary breast cancer cells (2005) (56)
- Transactivation of human hepatitis B virus X protein, HBx, operates through a mechanism distinct from protein kinase C and okadaic acid activation pathways. (1994) (55)
- Identification of recurrence-related microRNAs in the bone marrow of breast cancer patients. (2011) (54)
- Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil–epirubicin–cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy (2013) (54)
- Effect of carboplatin combined with whole body hyperthermia on normal tissue and tumor in rats. (1991) (53)
- Evaluating the 21-gene assay Recurrence Score® as a predictor of clinical response to 24 weeks of neoadjuvant exemestane in estrogen receptor-positive breast cancer (2013) (52)
- Regulation of Immunoproteasome Function in the Lung (2015) (52)
- Ki67 index changes, pathological response and clinical benefits in primary breast cancer patients treated with 24 weeks of aromatase inhibition (2011) (51)
- Prognostic value of the combination of epidermal growth factor receptor and c-erbB-2 in breast cancer. (2003) (51)
- Histidine at position 61 and its adjacent amino acid residues are critical for the ability of SLAM (CD150) to act as a cellular receptor for measles virus. (2003) (50)
- Abstract S1-07: A phase III trial of adjuvant capecitabine in breast cancer patients with HER2-negative pathologic residual invasive disease after neoadjuvant chemotherapy (CREATE-X, JBCRG-04) (2016) (49)
- A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer (2013) (47)
- Expression of Ets‐1 transcription factor is correlated with penetrating tumor progression in patients with squamous cell carcinoma of the esophagus (2000) (47)
- Impact of breast cancer diagnosis and treatment on women's sexuality: a survey of Japanese patients (2008) (46)
- EGFR, c-erbB2 and p53 protein in the primary lesions and paired metastatic regional lymph nodes in breast cancer. (2002) (46)
- Improved surgical results after combining preoperative hyperthermia with chemotherapy and radiotherapy for patients with carcinoma of the rectum (1997) (45)
- Prognostic significance of the coexpression of p53 protein and c-erbB2 in breast cancer. (2003) (44)
- S100a4 Is Secreted by Alternatively Activated Alveolar Macrophages and Promotes Activation of Lung Fibroblasts in Pulmonary Fibrosis (2018) (43)
- Late phase II clinical study of vinorelbine monotherapy in advanced or recurrent breast cancer previously treated with anthracyclines and taxanes. (2005) (43)
- Accuracy of magnetic resonance imaging for predicting pathological complete response of breast cancer after neoadjuvant chemotherapy: association with breast cancer subtype (2016) (42)
- CYFRA 21‐1 determination in patients with esophageal squamous cell carcinoma (2000) (42)
- Multidrug resistance‐associated protein expression in clinical gastric carcinoma (1996) (42)
- Immunohistochemical status of the p53 protein and Ki-67 antigen using biopsied specimens can predict a sensitivity to neoadjuvant therapy in patients with esophageal cancer. (2000) (42)
- Detection of occult cancer cells in peripheral blood and bone marrow by quantitative RT-PCR assay for cytokeratin-7 in breast cancer patients. (2005) (42)
- Long term survival of patients with stage IV gastric carcinoma (1998) (41)
- Modulation of thymidine phosphorylase by neoadjuvant chemotherapy in primary breast cancer (2004) (41)
- Colour Doppler sonography of breast masses: a multiparameter analysis. (1997) (41)
- Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients With an Initial Diagnosis of Cytology-Proven Lymph Node-Positive Breast Cancer. (2016) (40)
- Generation of Measles Virus with a Segmented RNA Genome (2006) (39)
- Intratumoral neovascularization and growth pattern in early gastric carcinoma (1999) (38)
- Concurrent overexpression of ETS‐1 and C‐met correlates with a phenotype of high cellular motility in human esophageal cancer (2002) (38)
- Pattern of Tumor Shrinkage during Neoadjuvant Chemotherapy Is Associated with Prognosis in Low-Grade Luminal Early Breast Cancer. (2018) (38)
- Correlation between sialyl Tn antigen and lymphatic metastasis in patients with Borrmann type IV gastric carcinoma. (1995) (38)
- Features of Microsatellite Instability in Colorectal Cancer: Comparison between Colon and Rectum (2001) (38)
- First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study (2011) (38)
- Measles Virus Mutants Possessing the Fusion Protein with Enhanced Fusion Activity Spread Effectively in Neuronal Cells, but Not in Other Cells, without Causing Strong Cytopathology (2014) (37)
- Measles Virus Nonstructural C Protein Modulates Viral RNA Polymerase Activity by Interacting with Host Protein SHCBP1 (2013) (37)
- Prognostic significance of lymphocyte infiltration following preoperative chemoradiotherapy and hyperthermia for esophageal cancer. (2001) (37)
- Alcohol consumption and cigarette smoking in relation to high frequency of p53 protein accumulation in oesophageal squamous cell carcinoma in the Japanese (2000) (37)
- Evaluation of circulating tumor cells in patients with breast cancer: multi-institutional clinical trial in Japan (2008) (36)
- Frequency of Microsatellite Instability inBreast Cancer Determined by High-Resolution Fluorescent Microsatellite Analysis (2000) (36)
- Efficient rescue of measles virus from cloned cDNA using SLAM-expressing Chinese hamster ovary cells. (2005) (36)
- Ipsilateral breast tumor recurrence (IBTR) in patients with operable breast cancer who undergo breast‐conserving treatment after receiving neoadjuvant chemotherapy (2012) (36)
- An integrated microsatellite length analysis using an automated fluorescent DNA sequencer. (1996) (36)
- Efficacy of goserelin plus anastrozole in premenopausal women with advanced or recurrent breast cancer refractory to an LH-RH analogue with tamoxifen: Results of the JMTO BC08-01 phase II trial (2013) (36)
- Survival of HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy plus trastuzumab: a multicenter retrospective observational study (JBCRG-C03 study) (2014) (36)
- The multicentric occurrence of squamous epithelial dysplasia and squamous cell carcinoma in the esophagus (1994) (35)
- Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel (2018) (34)
- Palbociclib in combination with letrozole in patients with estrogen receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients (2018) (34)
- Surgical treatment for gastric carcinomas with concomitant hepatic metastasis. (1996) (34)
- A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer (2014) (33)
- Measles Viruses Possessing the Polymerase Protein Genes of the Edmonston Vaccine Strain Exhibit Attenuated Gene Expression and Growth in Cultured Cells and SLAM Knock-In Mice (2008) (33)
- Palbociclib in combination with fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-3 subgroup analysis of Japanese patients (2018) (32)
- Phase I dose‐escalation trial to repurpose propagermanium, an oral CCL2 inhibitor, in patients with breast cancer (2020) (32)
- Predictive value of CD24 and CD44 for neoadjuvant chemotherapy response and prognosis in primary breast cancer patients. (2010) (32)
- Measles virus receptors and tropism. (2006) (32)
- Overexpression of p53 is associated with growth pattern and prognosis in advanced gastric cancer. (1997) (32)
- A dominant negative mutation of transforming growth factor- β receptor type II gene in microsatellite stable oesophageal carcinoma (2000) (31)
- The relation of alcohol consumption and cigarette smoking to the multiple occurrence of esophageal dysplasia and squamous cell carcinoma. (2002) (30)
- Growth pattern and p53 overexpression in patients with early gastric cancer (1995) (30)
- Clinical significance of the expression of autophagy-associated marker, beclin 1, in breast cancer patients who received neoadjuvant endocrine therapy (2016) (29)
- The Receptor-Binding Site of the Measles Virus Hemagglutinin Protein Itself Constitutes a Conserved Neutralizing Epitope (2013) (28)
- Cell-to-Cell Measles Virus Spread between Human Neurons Is Dependent on Hemagglutinin and Hyperfusogenic Fusion Protein (2018) (28)
- Preoperative hyperthermochemoradiotherapy for patients with rectal cancer (1989) (28)
- Effect of adriamycin combined with whole body hyperthermia on tumor and normal tissues. (1991) (27)
- Palbociclib in combination with letrozole as first‐line treatment for advanced breast cancer: A Japanese phase II study (2018) (27)
- Prognostic value of p53 protein expression in breast cancer; An immunohistochemical analysis of frozen sections in 514 Japanese women (2001) (27)
- Measles Virus-Induced Immunosuppression in SLAM Knock-In Mice (2010) (27)
- p53 Protein Accumulation in Multiple Oesophageal Squamous Cell Carcinoma: Relationship to Risk Factors (2002) (27)
- Clinical Significance of Extracapsular Invasion at Sentinel Lymph Nodes in Breast Cancer Patients with Sentinel Lymph Node Involvement (2015) (26)
- Subjective and Objective Assessment of Edema during Adjuvant Chemotherapy for Breast Cancer Using Taxane-Containing Regimens in a Randomized Controlled Trial: The National Surgical Adjuvant Study of Breast Cancer 02 (2012) (26)
- Scientific basis for the combination of tegafur with uracil. (1997) (26)
- Prognostic significance of subtype and pathologic response in operable breast cancer; a pooled analysis of prospective neoadjuvant studies of JBCRG (2015) (25)
- Haematological toxicity of carboplatin and cisplatin combined with whole body hyperthermia in rats. (1993) (25)
- Coexistence of intraepithelial carcinoma and glandular differentiation in esophageal squamous cell carcinoma (1988) (25)
- Circulating Pre-microRNA-488 in Peripheral Blood Is a Potential Biomarker for Predicting Recurrence in Breast Cancer (2018) (25)
- Comparison of an AC‐taxane versus AC‐free regimen and paclitaxel versus docetaxel in patients with lymph node‐positive breast cancer: Final results of the National Surgical Adjuvant Study of Breast Cancer 02 trial, a randomized comparative phase 3 study (2017) (25)
- Cystoid Macular Edema during Treatment with Paclitaxel and Bevacizumab in a Patient with Metastatic Breast Cancer: A Case Report and Literature Review (2017) (24)
- Treatment and prognosis of breast cancer patients with brain metastases according to intrinsic subtype. (2014) (24)
- Esophageal hemangioma: a case report and review of the literature. (1999) (24)
- Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancer (2010) (24)
- Thermosensing Function of the Escherichia coli Redox Sensor Aer (2010) (22)
- Incidentally detected lesions on contrast‐enhanced MR imaging in candidates for breast‐conserving therapy: Correlation between MR findings and histological diagnosis (2006) (22)
- First report of eribulin in combination with pertuzumab and trastuzumab for advanced HER2-positive breast cancer. (2017) (22)
- Significant survival improvement of patients with recurrent breast cancer in the periods 2001-2008 vs. 1992-2000 (2011) (21)
- Recent advances in preoperative hyperthermochemoradiotherapy for patients with esophageal cancer (1998) (21)
- Persistence and discontinuation of adjuvant endocrine therapy in women with breast cancer (2014) (21)
- Prognostic value of DNA ploidy in 653 Japanese women with node-negative breast cancer (2001) (21)
- Preparation of Cross-Linked Ultrathin Films Based on Layer-by-Layer Assembly of Polymers (1999) (21)
- Apoptosis and p53 overexpression in human rectal cancer; relationship with response to hyperthermo-chemo-radiotherapy. (2001) (19)
- Comparison of different definitions of pathologic complete response in operable breast cancer: a pooled analysis of three prospective neoadjuvant studies of JBCRG (2014) (19)
- Interim analysis of a phase II trial of cyclophosphamide, epirubicin and 5-fluorouracil (CEF) followed by docetaxel as preoperative chemotherapy for early stage breast carcinoma (2005) (19)
- Predictions of the pathological response to neoadjuvant chemotherapy in patients with primary breast cancer using a data mining technique (2012) (19)
- Corrigendum to "3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3)" [Breast 31 (February 2017) 244-259]. (2017) (18)
- Occurrence of esophageal carcinoma after gastrectomy (1989) (18)
- Helix pomatia agglutinin binding activity and lymph node metastasis in patients with gastric cancer. (1994) (18)
- Protective effect of ICRF-187 against normal tissue injury induced by adriamycin in combination with whole body hyperthermia. (1991) (18)
- Prediction of postoperative disease-free survival and brain metastasis for HER2-positive breast cancer patients treated with neoadjuvant chemotherapy plus trastuzumab using a machine learning algorithm (2018) (17)
- Increased therapeutic efficacy induced by tumor necrosis factor alpha combined with platinum complexes and whole-body hyperthermia in rats. (1992) (17)
- Outcomes of fulvestrant therapy among japanese women with advanced breast cancer: a retrospective multicenter cohort study (JBCRG-C06; Safari) (2017) (17)
- A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer (2020) (16)
- Chemotherapy resistant sarcoma treated with whole body hyperthermia (WBH) combined with 1-3-bis(2-chloroethyl)-1-nitrosourea (BCNU). (1992) (16)
- Changes in Recurrence Score by neoadjuvant endocrine therapy of breast cancer and their prognostic implication (2019) (16)
- Comparison of the immunohistochemical expression of EGFR, c-erbB2 and p53 protein between primary and recurrent breast cancer (2002) (16)
- A comparative epigenome analysis of gammaherpesviruses suggests cis-acting sequence features as critical mediators of rapid polycomb recruitment (2019) (16)
- Imatinib could be a new strategy for pulmonary hypertension caused by pulmonary tumor thrombotic microangiopathy in metastatic breast cancer (2016) (16)
- Frequent Loss of Heterozygosity but Rare Microsatellite Instability in Oesophageal Cancer in Japanese and Chinese Patients (2004) (15)
- Sequence dependence of the hyperthermic potentiation of carboplatin-induced cytotoxicity and intracellular platinum accumulation in HeLa cells. (1993) (15)
- Relationship between body mass index and preoperative treatment response to aromatase inhibitor exemestane in postmenopausal patients with primary breast cancer. (2012) (14)
- Chemotherapy-induced amenorrhea and the resumption of menstruation in premenopausal women with hormone receptor-positive early breast cancer (2017) (14)
- Cytokeratin staining reveals micrometastasis in lymph nodes of early gastric cancer. (1995) (14)
- Mutation status of RAD51C,PALB2 and BRIP1 in 100 Japanese familial breast cancer cases without BRCA1 and BRCA2 mutations (2017) (14)
- A Japanese phase I study of continuous oral capecitabine in patients with malignant solid tumors (2005) (14)
- Randomized phase II study of nab‐paclitaxel as first‐line chemotherapy in patients with HER2‐negative metastatic breast cancer (2017) (14)
- Erratum to "Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up": Annals of Oncology 30; 2019: 1194-1220. (2020) (14)
- Annexin A2 Mediates the Localization of Measles Virus Matrix Protein at the Plasma Membrane (2018) (14)
- Impact of clinical response to neoadjuvant endocrine therapy on patient outcomes: a follow-up study of JFMC34-0601 multicentre prospective neoadjuvant endocrine trial (2018) (13)
- Tumor-infiltrating lymphocytes affect the efficacy of trastuzumab-based treatment in human epidermal growth factor receptor 2-positive breast cancer (2018) (13)
- Actin-Modulating Protein Cofilin Is Involved in the Formation of Measles Virus Ribonucleoprotein Complex at the Perinuclear Region (2015) (13)
- Macroscopic intraoperative diagnosis of serosal invasion and clinical outcome of gastric cancer: Risk of underestimation (1995) (13)
- Dose-Finding Phase I and Pharmacokinetic Study of Capecitabine (Xeloda) in Combination with Epirubicin and Cyclophosphamide (CEX) in Patients with Inoperable or Metastatic Breast Cancer (2008) (13)
- Clinical significance of gene mutation in ctDNA analysis for hormone receptor-positive metastatic breast cancer (2020) (13)
- Dosage of capecitabine and cyclophosphamide combination therapy in patients with metastatic breast cancer. (2007) (13)
- Clinicopathologic features of patients with oesophageal cancer obtaining a histological complete response for preoperative hyperthermo-chemo-radiotherapy. (1998) (13)
- Sensitive detection of measles virus infection in the blood and tissues of humanized mouse by one-step quantitative RT-PCR (2013) (12)
- Correlation between docetaxel-induced skin toxicity and the use of steroids and H2 blockers: a multi-institution survey (2009) (12)
- Peritoneal dissemination after a curative gastrectomy in patients with undifferentiated adenocarcinoma of the stomach. (1994) (12)
- A new molecular-based lymph node staging classification determines the prognosis of breast cancer patients (2017) (12)
- Hyperthermia for rectal cancer. (2002) (12)
- Prognostic Significance of the Combination of Biological Parameters in Breast Cancer (2003) (12)
- [Assessment of goserelin treatment in adjuvant therapy for premenopausal patients with breast cancer in Japan-zoladex breast cancer study group trial-B]. (2005) (11)
- Oral combination chemotherapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: a phase II study (2010) (11)
- Oxidation of Sintered Aluminum Nitride by Oxygen and Water Vapor (1992) (11)
- Prevalence of disease-causing genes in Japanese patients with BRCA1/2-wildtype hereditary breast and ovarian cancer syndrome (2020) (11)
- DNA aneuploidy assessment of the effectiveness of hyperthermo‐chemo‐radiotherapy for esophageal carcinoma (1989) (11)
- Giant cell tumor of soft tissue of the breast: Case report with H3F3A mutation analysis and review of the literature. (2019) (10)
- DNA Aneuploidy in Relation to the Combination of Analysis of Estrogen Receptor, Progesterone Receptor, p53 Protein and Epidermal Growth Factor Receptor in 498 Breast Cancers (2002) (10)
- Optical Second Harmonic Generation in Alternately Assembled Dye-Polyion Multilayers (1997) (10)
- Efficacy of fulvestrant 500 mg in Japanese postmenopausal advanced/recurrent breast cancer patients and factors associated with prolonged time-to-treatment failure (2015) (10)
- Altered lymphatic drainage patterns in re-operative sentinel lymph node biopsy for ipsilateral breast tumor recurrence (2019) (10)
- Prevalence of disease-causing genes in Japanese patients with BRCA1/2-wildtype hereditary breast and ovarian cancer syndrome. (2020) (10)
- Flow cytometric analysis of DNA ploidy in primary, metastatic and recurrent breast cancers. (2002) (10)
- Ten‐year survivors after surgical treatment and perioperative irradiation for esophageal carcinoma (1991) (10)
- Efficacy and safety of trastuzumab, lapatinib, and paclitaxel neoadjuvant treatment with or without prolonged exposure to anti-HER2 therapy, and with or without hormone therapy for HER2-positive primary breast cancer: a randomised, five-arm, multicentre, open-label phase II trial (2018) (10)
- Macroscopic appearance and biological character of gastric cancer invading the muscularis propria. (1996) (9)
- The efficacy and safety of FSK0808, filgrastim biosimilar: a multicenter, non-randomized study in Japanese patients with breast cancer. (2013) (9)
- Neoadjuvant endocrine therapy with exemestane followed by response‐guided combination therapy with low‐dose cyclophosphamide in postmenopausal patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study (2018) (9)
- Anastrozole versus tamoxifen as adjuvant therapy for Japanese postmenopausal patients with hormone-responsive breast cancer: efficacy results of long-term follow-up data from the N-SAS BC 03 trial (2014) (9)
- Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERA (2020) (9)
- Sensitization of chemotherapy by anti-HER (2004) (9)
- Surgical treatment and prognosis for patients with gastric cancer lesions larger than ten centimeters in size. (1995) (9)
- Both type I and type III interferons are required to restrict measles virus growth in lung epithelial cells (2018) (9)
- A CASE OF GRANULOMATOUS MASTITIS WITH CORYNEBACTERIUM KROPPENSTEDTII INFECTION (2008) (8)
- Tolerability of Therapies Recommended for the Treatment of Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer. (2016) (8)
- Circulating PD-1 mRNA in Peripheral Blood is a Potential Biomarker for Predicting Survival of Breast Cancer Patients (2020) (8)
- Fulvestrant for the treatment of advanced breast cancer in postmenopausal women: a Japanese study. (2004) (8)
- Characteristics of adverse events of endocrine therapies among older patients with breast cancer (2019) (8)
- [Advances in the treatment of colorectal cancer]. (1996) (8)
- ORF23 of murine gammaherpesvirus 68 is non-essential for in vitro and in vivo infection. (2012) (8)
- Aromatase inhibitors with or without luteinizing hormone–releasing hormone agonist for metastatic male breast cancer: report of four cases and review of the literature (2016) (8)
- Histological classification of invasive ductal carcinoma and the biological parameters in breast cancer (2003) (8)
- Prognostic significance of histological therapeutic effect in preoperative chemotherapy for breast cancer (2016) (8)
- Neutropenia management with palbociclib in Japanese patients with advanced breast cancer (2019) (8)
- Murine gammaherpesvirus 68 glycoprotein 150 does not contribute to latency amplification in vivo (2012) (8)
- Team approach to providing the multidisciplinary medical treatment derived by the patients and their family (2005) (7)
- Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial. (2021) (7)
- Screening for COVID-19 in Symptomatic Cancer Patients in a Cancer Hospital (2020) (7)
- Implementation of institutional antiemetic guidelines for low emetic risk chemotherapy with docetaxel: a clinical and cost evaluation (2012) (7)
- Clinical value of SDI test for predicting effect of postoperative chemotherapy for patients with gastric cancer. (1994) (7)
- Randomized phase II study of weekly paclitaxel with or without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA HER2-negative breast cancer. (2014) (7)
- A Case of Recurrent Breast Cancer Identified by Pulmonary Tumor Thrombotic Microangiopathy (2017) (7)
- [Treatment strategy for and clinical results in patients with recurrent esophageal cancer]. (1999) (7)
- Efficacy of the eribulin, pertuzumab, and trastuzumab combination therapy for human epidermal growth factor receptor 2–positive advanced or metastatic breast cancer: a multicenter, single arm, phase II study (JBCRG-M03 study) (2020) (7)
- Multicenter study of primary systemic therapy with docetaxel, cyclophosphamide and trastuzumab for HER2-positive operable breast cancer: the JBCRG-10 study (2019) (7)
- Usefulness of second-look ultrasonography using anatomical breast structures as indicators for magnetic resonance imaging-detected breast abnormalities (2019) (6)
- Insulin-like growth factor II messenger RNA-binding protein-3 is an indicator of malignant phyllodes tumor of the breast. (2016) (6)
- Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients: extended follow-up of JBCRG-cohort study 01 (2020) (6)
- N-Cadherin mRNA Levels in Peripheral Blood Could Be a Potential Indicator of New Metastases in Breast Cancer: A Pilot Study (2020) (6)
- Eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer patients stratified by homologous recombination deficiency status: a multicenter randomized phase II clinical trial (2021) (6)
- Evaluating the usefulness of breast strain elastography for intraductal lesions (2021) (6)
- Efficacy of Adjuvant Combination Therapy With Trastuzumab and Chemotherapy in HER2-positive Early Breast Cancer: A Single Institutional Cohort Study from Clinical Practice (2020) (6)
- Vascular endothelial growth factor receptor-1 mRNA overexpression in peripheral blood as a useful prognostic marker in breast cancer (2012) (6)
- Deposition of photo-generated mixed-valent Fe(II)Fe(III) complexes at the surface of Langmuir monolayers (1997) (6)
- Correction to: Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan ( (2020) (6)
- Hypercalcemia related to the poor prognosis of patients with squamous cell carcinoma of the esophagus (1989) (6)
- Prospective observational study of bevacizumab combined with paclitaxel as first- or second-line chemotherapy for locally advanced or metastatic breast cancer: the JBCRG-C05 (B-SHARE) study (2020) (6)
- CD44v9 as a poor prognostic factor of triple-negative breast cancer treated with neoadjuvant chemotherapy (2018) (6)
- Oral combination chemotherapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: phase II study. (2009) (6)
- Surgical excision without whole breast irradiation for complete resection of ductal carcinoma in situ identified using strict, unified criteria. (2017) (5)
- Effect of HER2 status on risk of recurrence in women with small, node‐negative breast tumours (2011) (5)
- Lysosome-Associated Membrane Proteins Support the Furin-Mediated Processing of the Mumps Virus Fusion Protein (2020) (5)
- Factors associated with prolonged overall survival in patients with postmenopausal estrogen receptor-positive advanced breast cancer using real-world data: a follow-up analysis of the JBCRG-C06 Safari study (2019) (5)
- Clinical outcomes and prognostic factors in patients with stage II-III breast cancer treated with neoadjuvant chemotherapy followed by surgery and postmastectomy radiation therapy in the modern treatment era (2018) (5)
- Preoperative systemic therapy in locoregional management of early breast cancer: highlights from the Kyoto Breast Cancer Consensus Conference (2012) (5)
- Changes in Treatment Behavior during the COVID-19 Pandemic among Patients at a Cancer Hospital (2021) (5)
- Meta-analysis of nanoparticle albumin-bound paclitaxel used as neoadjuvant chemotherapy for operable breast cancer based on individual patient data (JBCRG-S01 study) (2021) (5)
- Pharmacogenomic–pharmacokinetic study of selective estrogen-receptor modulators with intra-patient dose escalation in breast cancer (2019) (5)
- The Expression Level of PD-L1 (CD274) mRNA in Peripheral Blood Is a Potential Biomarker for Predicting Recurrence in Breast Cancer (2020) (5)
- Primary intraorbital meningiomas: A roentgenologic study (1973) (5)
- A randomized, open-label, Phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab and chemotherapy: the Japan Breast Cancer Research Group-M05 PRECIOUS study. (2018) (5)
- Factors associated with prolonged time to treatment failure with fulvestrant 500 mg in patients with post-menopausal estrogen receptor-positive advanced breast cancer: a sub-group analysis of the JBCRG-C06 Safari study (2018) (5)
- Poly(L-glutamic acid)-poly(oxyethylene glycol) systems: Perpetuated cholesteric liquid crystal structures in noncrosslinked and crosslinked solid films (1980) (5)
- Numerical Analysis of Unshrouded Impeller Flowfield in the LE-X Liquid Hydrogen Pump (2017) (5)
- Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients (2015) (5)
- Phase I dose-finding study of eribulin and capecitabine for metastatic breast cancer: JBCRG-18 cape study (2017) (5)
- Serial circulating tumor DNA monitoring of CDK4/6 inhibitors response in metastatic breast cancer (2022) (5)
- Cytogenetic analysis of metaplastic squamous cell carcinoma of the breast inter- and intratumoral heterogeneity (2017) (4)
- Practical Application of the Continual Reassessment Method to a Phase I Dose-Finding Trial in Advanced Breast Cancer (2007) (4)
- The utility of DHL-HisZnNa, a novel antioxidant, against anticancer agent-induced alopecia in breast cancer patients: a multicenter phase II clinical trial (2019) (4)
- A case of HER-2-positive advanced inflammatory breast cancer with invasive micropapillary component showing a clinically complete response to concurrent trastuzumab and paclitaxel treatment (2010) (4)
- Predictive Factors and Value of ypN+ after Neoadjuvant Chemotherapy in Clinically Lymph Node-Negative Breast Cancer (2016) (4)
- Preoperative u-PAR Gene Expression in Bone Marrow Indicates the Potential Power of Recurrence in Breast Cancer Cases (2009) (4)
- Palbociclib‐letrozole as first‐line treatment for advanced breast cancer: Updated results from a Japanese phase 2 study (2020) (4)
- Analysis of subsequent therapy in Japanese patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer who received palbociclib plus endocrine therapy in PALOMA-2 and -3 (2020) (4)
- Clinicopathological features of breast cancer patients with internal mammary and/or supraclavicular lymph node recurrence without distant metastasis (2020) (4)
- Brain metastasis of breast cancer (2004) (4)
- A meta-analysis of clinical benefit rates for fulvestrant 500 mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer (2019) (4)
- Distinct Clinicopathologic Features and Possible Pathogenesis of Localized ALK-positive Histiocytosis of the Breast (2021) (4)
- Sentinel lymph node biopsy following neoadjuvant chemotherapy in clinically node-negative breast cancer patients. (2011) (4)
- Abstract GS1-09: Addition of S-1 to endocrine therapy in the post-operative adjuvant treatment of hormone receptor-positive and human epidermal growth factor receptor 2-negative primary breast cancer: A multicenter, open-label, phase 3 randomized trial (POTENT trial) (2020) (4)
- Eribulin-induced liver dysfunction as a prognostic indicator of survival of metastatic breast cancer patients: a retrospective study (2016) (4)
- Application of a continual reassessment method to a phase I clinical trial of capecitabine in combination with cyclophosphamide and epirubicin (CEX) for inoperable or recurrent breast cancer. (2004) (4)
- A multicenter, phase II study of epirubicin/cyclophosphamide followed by docetaxel and concurrent trastuzumab as primary systemic therapy for HER-2 positive advanced breast cancer (the HER2NAT study) (2013) (4)
- The comparison of the anatomic stage and pathological prognostic stage according to the AJCC 8th edition for the prognosis in Japanese breast cancer patients: data from a single institution (2020) (4)
- Prognostic impact and possible pathogenesis of lymph node metastasis in ductal carcinoma in situ of the breast (2018) (4)
- The effect of pathological response of multicenter phase II trial of fluorouracil, epirubicin, cyclophosphamide (FEC 100) followed by docetaxel (DOC 75) in primary operable breast cancer (JBCRG01: Japan Breast Cancer Research Group) (2006) (4)
- The ELEANOR noncoding RNA expression contributes to cancer dormancy and predicts late recurrence of estrogen receptor‐positive breast cancer (2022) (4)
- Can patients with metastatic breast cancer be cured after introduction of newer and more effective agents? (2012) (4)
- Participants in a randomized controlled trial had longer overall survival than non-participants: a prospective cohort study (2019) (4)
- Impact of Primary Pegfilgrastim Prophylaxis on Relative Dose Intensity in Neoadjuvant/Adjuvant FEC-100 Chemotherapy (2020) (4)
- Assessment of axillary node status by ultrasound after neoadjuvant chemotherapy in patients with clinically node-positive breast cancer according to breast cancer subtype (2021) (3)
- Advances in Brief p 53 Polymorphism in Human Papillomavirus-associated Esophageal Cancer 1 (2000) (3)
- Myofibroblastoma of the breast showing rare palisaded morphology and uncommon desmin‐ and CD34‐negative immunophenotype: A case report (2021) (3)
- Laparoscopic repair of a perforated duodenal ulcer in two patients (2010) (3)
- Development of Breast Cancer Therapy: Biomarker-Driven and Response-Guided Approaches in a Neoadjuvant Setting (2015) (3)
- Five screening-detected breast cancer cases in initially disease-free BRCA1 or BRCA2 mutation carriers (2019) (3)
- GRHL2 motif is associated with intratumor heterogeneity of cis-regulatory elements in luminal breast cancer (2022) (3)
- Protective effect of NG-monomethyl-L-arginine against hypotension inducted by combined tumour necrosis factor-alpha and whole body hyperthermia in rats. (1996) (3)
- Abstract P1-14-02: Preoperative docetaxel (T) with or without capecitabine (X) following epirubicin, 5-fluorouracil and cyclophosphamide (FEC) in patients with operable breast cancer (OOTR N003): Results of comparative study and predictive marker analysis (2012) (3)
- Correlation between docetaxel-induced skin toxicity and the use of steroids and H2 blockers: A multi-institution survey. (2012) (3)
- Metastatic ovarian cancer spreading into mammary ducts mimicking an in situ component of primary breast cancer: a case report (2021) (3)
- Analysis of tumor infiltrating lymphocytes in HER2-positive primary breast cancer treated with neoadjuvant lapatinib and trastuzumab: The NeoLath study (JBCRG-16). (2016) (3)
- Murine gammaherpesvirus 68 ORF35 is required for efficient lytic replication and latency. (2015) (3)
- Assessment of a cancer genomic profile test for patients with metastatic breast cancer (2022) (3)
- Myocardial dysfunction caused by abemaciclib: a case report (2021) (3)
- OP9 Predictive value of CD24 and CD44 for response to neoadjuvant chemotherapy and prognosis in patients with primary breast cancer (2011) (3)
- Impact of Visceral Metastasis on Efficacy of Fulvestrant in Patients with Hormone Receptor-positive Recurrent Breast Cancer. (2018) (3)
- Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR (2022) (3)
- [High incidence-rate of oral mucositis in breast cancer patients receiving anthracycline-based chemotherapy (FEC100)]. (2012) (3)
- Pertuzumab retreatment for HER2‐positive advanced breast cancer: A randomized, open‐label phase III study (PRECIOUS) (2022) (2)
- Efficacy of first-line bevacizumab (Bev) combined with weekly paclitaxel (wPac) for HER2-negative metastatic breast cancer (MBC): Results of a Japanese phase II study (n=120). (2011) (2)
- Eribulin in combination with pertuzumab plus trastuzumab for HER2-positive advanced or recurrent breast cancer (JBCRG-M03). (2017) (2)
- Pathogenicity assessment of variants for breast cancer susceptibility genes based on BRCAness of tumor sample (2021) (2)
- Performance analysis of the anti-Ki67 antibody clone 30-9 for immunohistochemical staining of breast cancer (2020) (2)
- Significance of routine annual esophagram for early detection of carcinoma of the esophagus. (1997) (2)
- [Effect of adjuvant chemotherapy for patients with early gastric cancer]. (1994) (2)
- A diagnostic strategy for breast calcifications based on a long-term follow-up of 615 lesions (2019) (2)
- Prognostic impact of postoperative radiotherapy in patients with breast cancer and with pT1-2 and 1-3 lymph node metastases: A retrospective cohort study based on the Japanese Breast Cancer Registry. (2022) (2)
- A multicenter phase II study of primary systemic therapy epirubicin/cyclophosphamide followed by docetaxel plus concurrent trastuzumab for HER2-positive advanced breast cancer. (2010) (2)
- Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks' exemestane exposure in patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study (2019) (2)
- Combination chemotherapy with docetaxel and doxifluridine showed a beneficial outcome in advanced or recurrent breast cancer patients with longer disease-free interval. (2004) (2)
- Numerical Study of Tip Clearance Effects in a Centrifugal Pump with Unshrouded Impeller for Liquid Rocket Engines (2019) (2)
- Impact of serum vitamin D on the response and prognosis in breast cancer patients treated with neoadjuvant chemotherapy (2021) (2)
- Abstract P3-12-03: Adjuvant capecitabine in breast cancer patients with pathologic residual disease after neoadjuvant chemotherapy: First safety analysis of CREATE-X (JBCRG-04) (2013) (2)
- Abstract P5-21-07: Phase II study of eribulin in combination with pertuzumab plus trastuzumab for human epidermal growth factor receptor 2 (HER2)-positive advanced or metastatic breast cancer (2018) (2)
- Abstract PD3-11: A randomized, open-label, phase III trial of pertuzumab re-treatment in HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab, and chemotherapy: The Japan Breast Cancer Research Group-M05 (PRECIOUS) study (2021) (2)
- P203 Dual HER2 blockage with lapatinib and trastuzumab for Japanese patients with HER2+ breast cancer (2015) (2)
- Biomolecular Fluorescence Complementation Profiling and Artificial Intelligence Structure Prediction of the Kaposi’s Sarcoma-Associated Herpesvirus ORF18 and ORF30 Interaction (2022) (2)
- Missed opportunities and challenges for surgical breast cancer research in the era of personalized cancer treatment. (2019) (2)
- Survival Outcomes of Retreatment with Trastuzumab and Cytotoxic Chemotherapy for HER2-Positive Recurrent Patients With Breast Cancer Who Had Been Treated with Neo/adjuvant Trastuzumab Plus Multidrug Chemotherapy: A Japanese Multicenter Observational Study (2018) (2)
- [Cellular tropism and adaptation of the measles virus]. (2006) (2)
- [Multidisciplinary treatment and care for patients with breast cancer]. (2006) (2)
- [DNA ploidy pattern and p53 overexpression in gastric cancer]. (1995) (2)
- Predictive significance of HER2 intratumoral heterogeneity, determined by simultaneous gene and protein analysis, for resistance to trastuzumab-based treatments for HER2-positive breast cancer (2021) (2)
- Measles virus infects both polarized epithelial and immune cells using 3 distinctive receptor-binding sites on its hemagglutinin 4 5 (2008) (2)
- Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial. (2022) (2)
- The early onset of peripheral neuropathy might be a robust predictor for time to treatment failure in patients with metastatic breast cancer receiving chemotherapy containing paclitaxel (2017) (2)
- A multicenter phase II trial of the LH-RH analogue and an aromatase inhibitor combination in premenopausal patients with advanced or recurrent breast cancer refractory to an LH-RH analogue with tamoxifen: JMTO BC08-01. (2012) (2)
- A study of the recurrence score by the 21-gene signature assay as a predictor of clinical response to neoadjuvant exemestane for 24 weeks in estrogen-receptor-positive breast cancer. (2011) (2)
- Axial mixing of liquid in horizontal two phase slug flow (1987) (2)
- PD07-02: Docetaxel Is Superior to Paclitaxel Given Every Three Weeks in Post Operative Patients with Node-Positive Breast Cancer: Results of the Final Analyses of the NSAS-BC (National Surgical Adjuvant Study of Breast Cancer) 02 Trial from Japan. (2011) (2)
- An overview of the Japan Breast Cancer Research Group (JBCRG) activities (2013) (2)
- Long-Term Outcomes of a Randomized Study of Neoadjuvant Induction Dual HER2 Blockade with Trastuzumab and Lapatinib Followed by Weekly Paclitaxel Plus Dual HER2 Blockade for HER2-Positive Primary Breast Cancer (Neo-Lath Study) (2021) (2)
- The relationship between the expression of FOXA1 and GATA3 and the efficacy of neoadjuvant endocrine therapy (2017) (1)
- Phase II study of neoadjuvant chemotherapy with a metronomic regimen of paclitaxel + cyclophosphamide + capecitabine followed by 5-fluorouracil + epirubicin + cyclophosphamide in operable triple-negative breast cancer (JBCRG-13 study). (2013) (1)
- Abstract P3-14-12: High Risk of Recurrence in Japanese Patients with HER2-Positive T1N0 Breast Cancer (2010) (1)
- A phase II study of sequential treatment with anthracycline and taxane followed by eribulin in patients with HER2-negative, locally advanced breast cancer (JBCRG-17) (2021) (1)
- Clinical significance of HER2 intratumoral heterogeneity, determined by simultaneous gene and protein analysis, in HER2-positive breast cancer (2018) (1)
- Prospective observational cohort study of bevacizumab combined with paclitaxel as the first- or second-line chemotherapy for locally advanced or metastatic breast cancer (Study JBCRG-C05: B-SHARE) (2018) (1)
- Optimal duration of whole body hyperthermia when combined with cis-diamminedichloroplatinum(II). (1997) (1)
- P5-23-02: Clinicopathological Features of Young Patients Age <35 Years with Breast Cancer in Japan. (2011) (1)
- Abstract P1-03-08: Simultaneous analyses of HER2 gene and protein status can more precisely predict pathological complete response (pCR) to neoadjuvant trastuzumab with chemotherapy in primary HER2-positive breast cancer (2017) (1)
- Abstract P3-10-01: Randomized phase III trial of taxanes versus S-1 as first-line chemotherapy for metastatic breast cancer (SELECT BC: CSPOR- MBC01) (2015) (1)
- Label‐free multiphoton excitation imaging as a promising diagnostic tool for breast cancer (2022) (1)
- Certification of Biological Character and Therapy in Regard to the Recurrence of the Gastric Cancer (1994) (1)
- Smartphone Psychotherapy Reduces Fear of Cancer Recurrence Among Breast Cancer Survivors: A Fully Decentralized Randomized Controlled Clinical Trial (J-SUPPORT 1703 Study) (2022) (1)
- Bolero-2: A Randomized Phase III Study of Everolimus in Combination with Exemestane: Results of the Japanese Subgroup Analysis (2012) (1)
- A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer (2020) (1)
- A multicenter, randomized phase II study of neoadjuvant chemotherapy including trastuzumab with cyclophosphamide with docetaxel in patients with operable HER2-positive breast cancer (JBCRG-10 study). (2010) (1)
- [Study on CAF + medroxyprogesterone acetate (MPA) therapy for advanced or recurrent breast cancer--comparison between MPA 600 mg and 1,200 mg. Kyushu CAFT Therapy Study Group (Third Study)]. (1999) (1)
- Phase II study of bevacizumab (Bev) combined with weekly paclitaxel (wPac) as first-line therapy for Japanese patients (pts) with HER2-negative metastatic breast cancer (MBC). (2010) (1)
- Prospective cohort study: whether or not patients benefit from participation itself in randomized-controlled trials (SELECT BC ECO). (2014) (1)
- Characteristics of female breast cancer in japan: annual report of the National Clinical Database in 2018 (2022) (1)
- Safety of trastuzumab in HER2-positive primary breast cancer in Japan: Initial safety report for the large-scale cohort study (JBCRG C-01). (2013) (1)
- Differences of TILs, hormone receptor, and HER2 status between primary and metastatic tumors. (2018) (1)
- A study of metastatic mode and intraoperative diagnosis on nodal involvement in patients with early gastric cancer. (1987) (1)
- Bevacizumab plus paclitaxel optimization study with interventional maintenance endocrine therapy in advanced or metastatic ER-positive HER2-negative breast cancer: JBCRG-M04 (BOOSTER) trial. (2014) (1)
- Anxiety and related factors among parents of patients with breast cancer after surgery in Japan: A multi-informant and multilevel study. (2021) (1)
- In vivo growth regulation by cytokine in breast cancer cells showing an estradiol-inhibitive response in vitro. (1997) (1)
- Assessment of the management of carcinomatous meningitis from breast cancer globally: a study by the Breast International Group Brain Metastasis Task Force (2022) (1)
- Outcome of Radiation Therapy for Brain Metasases From Breast Cancer: A Multi-Center Experience in the Era of Trastuzumab (2007) (1)
- Prognosis of patients with gastric cancer and pyloric stenosis: histological differentiation. (1994) (1)
- The management of contralateral axillary sentinel lymph nodes detected by lymphoscintigraphy in a patient of breast cancer that had never undergone breast related medical treatment (2017) (1)
- Relationships between pathological factors and long-term outcomes in patients enrolled in two prospective randomized controlled trials comparing the efficacy of oral tegafur–uracil with CMF (N·SAS-BC 01 trial and CUBC trial) (2020) (1)
- Eribulin mesylate may improve the sensitivity of endocrine therapy in metastatic breast cancer (2016) (1)
- Clinical significance of the neutrophil-to-lymphocyte ratio in oligometastatic breast cancer (2022) (1)
- Anthracycline followed by trastuzumab is still one of treatment options for small tumor with node-negative HER2-positive breast cancer (2019) (1)
- Epitopea Conserved Neutralizing Virus Hemagglutinin Protein Itself The Receptor-Binding Site of the Measles (2014) (1)
- Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19) (2021) (1)
- Serum Concentration of Estrone (E1), not Estradiol (E2), is the Independent Predictive Factor of Response to Neo-Adjuvant Exemestane Treatment in Postmenopausal Breast Cancer Patients: JFMC 34-0601 TR (2012) (1)
- Abstract P6-08-21: Low body mass index (BMI) is associated with poor survival in Japanese patients with early breast cancer; an exploratory analysis of prospective randomized phase III trials N-SAS BC02 and 03 (2015) (1)
- Transcriptomic intratumor heterogeneity of breast cancer patient-derived organoids may reflect the unique biological features of the tumor of origin (2023) (1)
- Abstract OT1-12-04: A phase 3, open-label trial of neoadjuvant trastuzumab deruxtecan (T-DXd) monotherapy or T-DXd followed by THP compared with ddAC-THP in patients with high-risk HER2-positive early-stage breast cancer (DESTINY-Breast11) (2022) (1)
- Abstract P5-14-01: A meta-analysis of clinical benefit rates for fulvestrant 500 mg versus alternative therapies for treatment of postmenopausal, estrogen receptor-positive advanced breast cancer (2016) (1)
- Clinicopathological features of breast cancer patients with internal mammary and/or supraclavicular lymph node recurrence without distant metastasis (2020) (0)
- 89P Questionnaire survey on patients’ preference for orally disintegrating tablets or granules of S-1 in postoperative adjuvant treatment for breast cancer (2016) (0)
- Utility of Preoperative Computed Tomography Scans for Coronavirus Disease in a Cancer Treatment Center (2020) (0)
- Quantification of intratumoral heterogeneity of HER2 status in breast cancer. (2017) (0)
- Cyclophosphamide, epirubicin and fluorouracil followed by docetaxel (CEF-DOC) as preoperative chemotherapy in primary operable breast cancer: Evaluation of chemotherapeutic response by breast MRI. (2004) (0)
- P027 The analysis of cytogenetic intra-tumoral heterogeneity in squamous cell carcinoma of the breast (2015) (0)
- Treatment outcomes of stage IIIC breast cancer: a single institutional review (2017) (0)
- P20 31 MP – ANTITUMOR EFFECT AND NORMAL TISSUE TOXICITY OF TUMOR NECROSIS FACTOR COMBINED WITH WHOLE BODY HYPERTHERMIA AND CISPLATIN OR CARBOPLATIN IN RATS (1991) (0)
- Correction to: Neutropenia management with palbociclib in Japanese patients with advanced breast cancer (2019) (0)
- Abstract OT2-02-07: Fulvestrant with additional palbociclib in advanced or metastatic hormone receptor-positive HER2-negative breast cancer after progression to fulvestrant monotherapy: JBCRG- M07 (FUTURE trial) (2020) (0)
- Factors affecting prognosis in patients treated with bevacizumab plus paclitaxel as first-line chemotherapy for HER2-negative metastatic breast cancer: an international pooled analysis of individual patient data from four prospective observational studies (2022) (0)
- Is ypT0/isn0 acceptable for Japanese population? JBCRG’s perception. (2013) (0)
- [Results of survey conducted on perioperative chemotherapy and supportive care in primary breast cancer (JBCRG01)]. (2007) (0)
- The impact of obesity and endocrine therapy on the prognosis of premenopausal women with hormone receptor‐positive breast cancer: A single‐institute retrospective study (2022) (0)
- P20 21 MP – COMPARISON OF THE ACUTE AND CHRONIC NORMAL TISSUE TOXICITIES OF CISPLATIN AND CARBOPLATIN COMBINED WITH WHOLE BODY HYPERTHERMIA IN RATS (1991) (0)
- Correction: Chromatin profile-based identification of a novel ER-positive breast cancer subgroup with reduced ER-responsive element accessibility (2023) (0)
- Rates of Breast Cancer Screening in Fukuoka Prefecture (2011) (0)
- Abstract P5-01-03: Evaluation of novel diagnostic kits using the semi-dry dot-blot method combined with an automatic reader for detecting metastases in sentinel lymph nodes of patients with breast cancer: a multi-center prospective study (2023) (0)
- [Development of CDK4 & 6 Inhibitor Abemaciclib in Breast Cancer]. (2021) (0)
- Early recurrence of gastric cancer in a patient with chronic renal failure. (1995) (0)
- Lymphatic invasion is significantly associated with prognosis in patients with node-negative early luminal breast cancer (2017) (0)
- Abstract P2-18-03: Feasibility of sentinel node biopsy following neoadjuvant chemotherapy in cytology-proven node positive breast cancer before chemotherapy (2013) (0)
- 159PDNeoadjuvant therapy with trastuzumab emtansine and pertuzumab in patients with HER2-positive primary breast cancer (A randomized, phase 2 study; JBCRG-20) (2017) (0)
- Clinical Outcome and Prognostic Factors in Locally Advanced Breast Cancer Patients Treated With Neoadjuvant Chemotherapy Followed by Surgery and Postmastectomy Radiation Therapy (2016) (0)
- Overall survival of participants compared to non-participants in a randomized-controlled trial (SELECT BC): A prospective cohort study. (2016) (0)
- Abstract P4-14-07: Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 8–12 weeks' exemestane exposure for ER+/HER2– postmenopausal breast cancer patients (2019) (0)
- Abstract P1-16-07: Pharmacogenomics-pharmacokinetics study of selective estrogen-receptor modulators with intra-patient dose-escalation for Japanese breast cancer patients (2016) (0)
- P5-13-21: Japanese Patients with Discordance in Estrogen Receptor between Primary Breast Cancer and Recurrent Tumor Have a Poorer Outcome. (2011) (0)
- Dose-escalation phase I study in metastatic breast cancer patients with combination of paclitaxel and tegafur·uracil. (2010) (0)
- Abstract P3-06-18: Increase of serum androgen and its metabolites in postmenopausal primary breast cancer patients with disease progression during neo-adjuvant exemestane treatment; JFMC 34–0601 TR (2012) (0)
- Abstract PS9-52: A randomized phase II trial of interventions with frozen groves and compression stockings to prevent nab-paclitaxel induced chemotherapy-induced peripheral neuropathy (SPOT trial) (2021) (0)
- Challenging patient populations in breast cancer: Taxane resistance and triple‐negative receptor subtype (2008) (0)
- P287 Indication of PMRT associated with risk of locoregional and distant recurrence in patients with N1–3 axillary nodal metastasis (2015) (0)
- PRECIOUS: A randomized, open-label phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients who were previously treated with pertuzumab, trastuzumab, and chemotherapy. (2016) (0)
- Abstract P5-01-22: Genomic landscape of circulating tumor DNA in early-stage breast cancer (2020) (0)
- Abstract P6-06-20: Predictive factors for pathologic complete response and disease-free survival after neoadjuvant chemotherapy with trastuzumab: A multicenter retrospective observational study in patients with HER2-positive primary breast cancer (JBCRG-C03 study) (2013) (0)
- P278 Feasibility study of adjuvant fluorouracil/epirubicin/cyclophosphamide (FEC 100) followed by triweekly docetaxel (D) plus trastuzumab (H) in HER2/neu positive early breast cancer (2011) (0)
- Abstract P6-07-10: Cytogenetic analysis of squamous cell carcinoma of the breast reveals inter- and intra-tumoral heterogeneity (2016) (0)
- Title Evaluating the 21-gene assay Recurrence Score ® as a predictor of clinical response to 24 weeks of neoadjuvant exemestane in estrogen receptor-positive breast cancer (2018) (0)
- Trastuzumab and fulvestrant combination therapy for women with advanced breast cancer positive for hormone receptor and human epidermal growth factor receptor 2: a retrospective single-center study (2022) (0)
- Abstract OT2-07-05: A phase III trial to compare eribulin mesylate + trastuzumab (H) + pertuzumab (P) with paclitaxel or docetaxel + HP for HER2-positive advanced or metastatic breast cancer (JBCRG-M06/ EMERALD) (2019) (0)
- Contents Vol. 72, 2007 (2008) (0)
- Experimental and clinical studies on the thermosensitivity test by using the succinate dehydrogenase inhibition test (1993) (0)
- Abstract P3-14-05: Randomized phase II study of preoperative docetaxel and cyclophosphamide-containing chemotherapy for luminal-type breast cancer (2013) (0)
- P3-12-03: A Prognostic Index of Ipsilateral Breast Tumor Recurrence in Patients Treated with Breast-Conserving Surgery after Preoperative Chemotherapy: Validation of M.D. Anderson Prognostic Index. (2011) (0)
- [The point of the informed consent in a breast cancer chemotherapy]. (2012) (0)
- Utility of Repeat Sentinel Lymph Node Biopsy for cN0 Ipsilateral Breast Tumor Recurrence in Patients Initially Treated with Breast-Conserving Surgery and Sentinel Lymph Node Biopsy (2019) (0)
- Oncofertility-related psycho-educational therapy for young adult patients with breast cancer and their partners: randomized controlled trial. (2023) (0)
- Vascular endothelial growth factor receptor-1 mRNA overexpression in peripheral blood as a useful prognostic marker in breast cancer (2012) (0)
- ISS3-2-4Predictions of pathological response after preoperative chemotherapy plus trastuzumab in HER2-positive breast cancer (2015) (0)
- An intervention RCT-study aimed at improving mental health and increasing understanding of fertility preservation with Oncofertility! Psycho-Education And Couple Enrichment (O!PEACE) therapy. (2020) (0)
- [Docetaxel in combination with epirubicin as the first-line chemotherapy for advanced and recurrent breast cancer: a multicenter phase II study]. (2012) (0)
- Abstract P5-13-05: The relationship between the expression of FOXA1 and GATA3 and the efficacy of neoadjuvant endocrine therapy (2016) (0)
- Abstract PS2-32: Incidental malignant findings on pre-admission chest computed tomography scan for coronavirus disease screening in patients with breast cancer or other cancers (2021) (0)
- Assessment of a cancer genomic profile test for patients with metastatic breast cancer (2022) (0)
- Correction to: Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19) (2021) (0)
- P3-07-27: ROCK II Expression Can Be a Potential Marker of Non-Sentinel Lymph Node Metastasis in Breast Cancer Patients with Sentinel Lymph Node Involvement. (2011) (0)
- Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2:HER2 dimerization in a clinic-based cohort of patients with metastatic breast cancer (2007) (0)
- 1766P Longitudinal alteration of cytokine profile in the peripheral blood and clinical response for neoadjuvant chemotherapy in triple-negative breast cancer patients (translational research of the JBCRG-22 trial) (2021) (0)
- Abstract P1-15-02: Low incidence of hepatitis B reactivation after chemotherapy in Japanese breast cancer patients with resolved HBV (2022) (0)
- IS2. Breast Cancer (2012) (0)
- Abstract P2-14-17: Pooled analysis of long-term outcome of patients enrolled in two trials comparing the efficacy of oral tegafur-uracil with CMF (N-SAS-BC01 and CUBC trials) (2020) (0)
- Abstract P5-14-18: Indication of post-mastectomy radiation associated with risk of local recurrence in breast cancer patients with 1-3 lymph node metastasis (2013) (0)
- Abstract P4-02-13: The pattern of tumor shrinkage is associated with prognosis in low grade luminal early breast cancer during neoadjuvant chemotherapy (2016) (0)
- Subject Index Vol. 72, 2007 (2008) (0)
- 415 Comparison of two Phase II trials evaluating three dosing regimens of fulvestrant in Japanese vs non-Japanese postmenopausal women with advanced breast cancer (FINDER1 and FINDER2) (2010) (0)
- Impact of body mass index on the prognosis of Japanese women with operable hormone receptor-positive breast cancer: A single institutional retrospective study. (2021) (0)
- P213 Neoadjuvant nab-paclitaxel followed by FEC for operable breast cancer: KBC-SG 1103 trial (2015) (0)
- Aggressive recurrence of early breast invasive ductal carcinoma with gastric metastasis during adjuvant hormonal therapy (2016) (0)
- Japanese Multi-Institutional Feasibility Study of APBI Using Interstitial Brachytherapy (2011) (0)
- Initial assessment of a cancer genomic profile test for patients with metastatic breast cancer: a retrospective study (2021) (0)
- Abstract P4-12-02: Adjuvant trastuzumab improved the prognosis of HER2-positive early breast cancer: Single institutional cohort study from clinical practice (2016) (0)
- Prognosis and Clinicopathological Characteristics of Microinvasive Breast Carcinoma (2022) (0)
- Abstract P2-09-28: New quantitative diagnostic method by fluorescence nanoparticle for HER2 positive breast cancer treated with neoadjuvant lapatinib and trastuzumab: The Neo LaTH study (JBCRG-16TR) (2018) (0)
- [Comprehensive medicine for the patient with breast cancer]. (2007) (0)
- Abstract 3908: The mechanism of premetastatic niche formation through FBXW7/NOTCH/CCL2 pathway and clinical trial using CCL2 inhibitor “SK-818” for breast cancer patients (2017) (0)
- Abstract P3-06-26: Serum anti-p53 antibody titers predict pathological response to preoperative chemotherapy in women with HER2 positive or triple negative breast cancer. (2012) (0)
- The impact of intratumoral heterogeneity on the prognosis of ER-positive/HER2-negative breast cancer. (2014) (0)
- Validation of a nuclear grading system for resected stage I–IIIA, high-risk, node-negative invasive breast carcinoma in the N·SAS-BC 01 trial (2022) (0)
- Monitoring of therapeutic efficacy to CDK4/6 inhibitors and early detection of metastatic relapse in breast cancer by ultra-deep sequencing of plasma cell-free DNA. (2020) (0)
- P168 Time-to-failure in 1st-line endocrine therapy with ER+/HER2−metastatic breast cancer (2015) (0)
- A multicenter phase II trial of neoadjuvant letrozole plus low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer (JBCRG07): The efficacy and its correlation with circulating endothelial cells. (2011) (0)
- The Abnormal Expressions of c-erbB-2 or p53 Proteins are Significant Prognostic Factors in Gastric Cancer (1993) (0)
- P1-06-21: Relationship between Body Mass Index and Preoperative Treatment Response to Aromatase Inhibitor Exemestane in Postmenopausal Patients with Primary Breast Cancer. (2011) (0)
- PO104 PATIENTS WITH DISCORDANCE IN ESTROGEN RECEPTOR BETWEEN PRIMARY BREAST CANCERS AND RECURRENT TUMORS HAVE POOR OUTCOMES (2013) (0)
- Abstract PD7-05: A multicenter prospective study to predict pathologic complete response by vacuum-assisted breast biopsy based on MRI and US findings after neoadjuvant chemotherapy (2022) (0)
- Correction to: Phase I dose-finding study of eribulin and capecitabine for metastatic breast cancer: JBCRG-18 cape study (2017) (0)
- Activation of Akt correlates with resistance to endocrine therapy for metastatic breast cancer (2005) (0)
- Clinical Trial Note Application of a Continual Reassessment Method to a Phase I Clinical Trial of Capecitabine in Combination with Cyclophosphamide and Epirubicin (CEX) for Inoperable or Recurrent Breast Cancer (2004) (0)
- 65PD Significance of preoperative fine-needle aspiration biopsy for suspected cases of lymph node metastasis in primary breast cancer (2016) (0)
- Abstract P5-11-11: Influence of the adjuvant hormonal therapy on hormone sensitivity and survival outcomes in ER+ and HER2−advanced breast cancer: A subgroup analysis of the JBCRG-C06 Safari study (2020) (0)
- Retrospective study on the effectiveness of medroxyprogesterone acetate in the treatment of ER-positive/HER2-negative post-menopausal advanced breast cancer: an additional analysis of the JBCRG-C06 Safari study. (2022) (0)
- Microvessel quantification and its possible relation with liver metastasis in colorectal cancer (0)
- Future issues from our experiences of support to unaffected BRCA1/2 pathogenic variant carriers. (2022) (0)
- Abstract A29: Next-generation sequencing of circulating tumor DNA to monitor treatment response to CDK4/6 inhibitors in breast cancer (2020) (0)
- P113 The biology and prognosis of breast cancer in Japanese patients under 50 years of age (2011) (0)
- Abstract P4-08-29: Lymphatic invasion is an independent risk factor in patients with small node-negative luminal breast cancer (2019) (0)
- A nomogram to predict nonsentinel lymph node involvement in breast cancer patients with sentinel lymph node metastases. (2011) (0)
- Correction to: Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19) (2022) (0)
- 328P Patient-reported outcomes of a switch to maintenance endocrine therapy following induction chemotherapy versus continuation of chemotherapy in ER-positive HER2-negative metastatic breast cancer: A randomized, open-label, phase II clinical trial (2020) (0)
- P111 A phase 3, open-label trial of neoadjuvant trastuzumab deruxtecan (T-DXd) monotherapy or T-DXd followed by THP vs ddAC-THP in high-risk HER2-positive early-stage breast cancer (DESTINY-Breast11) (2023) (0)
- Only a few young patients aged 40 years with ‘high-risk’ breast cancer preserved fertility; report from actual survey in a Japanese cancer hospital (2018) (0)
- Ductal Carcinoma In situ Manageable by Active Surveillance (2018) (0)
- Estimation of absolute benefit of S-1 postoperative therapy for ER-positive, HER2-negative breast cancer: Exploratory analysis of the phase III potent trial. (2020) (0)
- Abstract PS1-19: The accuracy of axillary node assessment of ultrasound after neoadjuvant chemotherapy in clinically node positive patients (2021) (0)
- Abstract P3-13-06: Tailored neoadjuvant endocrine and chemo-endocrine therapy for postmenopausal patients with estrogen receptor-positive human epidermal growth factor receptor 2-negative primary breast cancer (2018) (0)
- Multidrug resistance‐associated protein expression in clinical gastric carcinoma (0)
- Efficacy study of sequential therapy with anthracycline, taxane, and eribulin in patients with HER2-negative locally advanced breast cancer (JBCRG-17). (2016) (0)
- Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel (2018) (0)
- P1-16-01: A Randomized, Double-Blinded, Controlled Study of Exemestane vs. Anastrozole for the First-Line Treatment of Postmenopausal Japanese Women with Hormone Receptor Positive Advanced Breast Cancer. (2011) (0)
- Abstract P3-19-27: Prognostic impact of postmastectomy radiation therapy in breast cancer patients with T1, 2 and 1-3 lymph nodes from Japan Breast Cancer Registry (2022) (0)
- Abstract P3-10-16: Predicting pathological complete response by the combination of microRNAs in patients with HER2-positive primary breast cancer who received neoadjuvant combination therapy of trastuzumab, lapatinib and paclitaxel: Results from JBCRG-16 (NeoLath) study (2019) (0)
- Haematological toxicity ofcarboplatin andcisplatin combined withwhole bodyhyperthermia inrats (1993) (0)
- Trastuzumab and fulvestrant combination therapy for women with advanced breast cancer positive for hormone receptor and human epidermal growth factor receptor 2: a retrospective single-center study (2022) (0)
- Sentinel node biopsy in Asian breast cancer patients: An observation study of 1,000 consecutive patients treated at a single institute. (2009) (0)
- Relationship of tumor and stromal autophagy and endocrine responsiveness in breast cancer tissues. (2013) (0)
- OP-ANNO180192 1634..1657 (2018) (0)
- Development of diagnostic kit for in vitro diagnostics of the TP53 signature in early breast cancer (2019) (0)
- Characteristics, treatment trends, and long-term outcomes of Japanese patients with pregnancy-associated breast cancer (PABC) (2022) (0)
- SY8-2THE CURRENT STATUS AND FUTURE PERSPECTIVES OF JBCRG IN JAPAN (2014) (0)
- Abstract P4-11-06: Effect of suppressed ovarian function on prognosis of premenopausal obese women with hormone receptor-positive breast cancer: A single-institute retrospective study (2022) (0)
- 302PFactors associated with prolonged time to treatment failure with fulvestrant 500 mg in patients with postmenopausal estrogen receptor-positive advanced/metastatic breast cancer (JBCRG-C06; Safari): A subgroup analysis (2017) (0)
- Clinical significance of the expression of autophagy-associated marker, beclin 1, in breast cancer patients who received neoadjuvant endocrine therapy (2016) (0)
- Endoscopic intratumoral injection of OK-432 prevents peritoneal recurrences in patients with gastric carcinoma. (1989) (0)
- Factors associated with overall survival after recurrence in patients with ER-positive/HER2-negative breast cancer: An ad-hoc analysis of the JBCRG-C06 Safari study (2021) (0)
- PO33 Clinical practice guideline for preservation of fertility in breast cancer patients in Japan (2014) (0)
- [Pharmacodynamic study on the effectiveness of UFT against cancer of gastro-intestinal (GI) tract]. (1993) (0)
- Abstract P1-13-15: Risk of late recurrence of hormone receptor positive breast cancer in cases with no recurrent disease at five years after surgery (2013) (0)
- Erratum to: Outcomes of trastuzumab therapy in HER2‑positive early breast cancer patients (2015) (0)
- Objective and Subjective Assessment of Edema during Adjuvant Chemotherapy Using Taxane-Containing Regimens in a Randomized Controlled Trial: National Surgical Adjuvant Study of Breast Cancer (NSAS-BC) 02. (2009) (0)
- Abstract P1-08-12: Trends in incidence of bilateral breast cancer: A Population-based comparative study of the United States and Japan (2019) (0)
- AOSOP16 DEVELOPMENT OF WEB TOOLS TO PREDICT PATHOLOGICAL RESPONSE TO NEOADJUVANT CHEMOTHERAPY AND AXILLARY LYMPH NODE METASTASIS IN BREAST CANCER PATIENTS (2013) (0)
- Significant survival improvement and prognostic factors of recurrent breast cancer after approval third generation aromatase inhibitors and trastuzumab (2011) (0)
- Survival in Cytologically Proven Node-Positive Breast Cancer Patients with Nodal Pathological Complete Response after Neoadjuvant Chemotherapy (2020) (0)
- Disparities in Access to Systemic Treatment for Breast Cancer in Thailand and Major Asian Territories (2022) (0)
- Peking University - Juntendo University Joint Symposium on Cancer Research and Treatment: Clinical Practice for Hereditary Breast and Ovarian Cancer (HBOC) in Japan (2017) (0)
- Title Clinical significance of the expression of autophagy-associated marker , beclin 1 , in breast cancer patients who (2019) (0)
- An all-oral combination of capecitabine (X) and cyclophosphamide (C): Findings from a phase I study and an additional feasibility study in patients (pts) with metastatic breast cancer (MBC) (2005) (0)
- Abstract P4-21-24: Development of mathematical prediction models to identify disease-free survival events for HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy and trastuzumab (2017) (0)
- Abstract P2-16-13: Meta-analysis of nanoparticle albumin-bound paclitaxel (Nab-PTX) used as a neoadjuvant chemotherapy for operable breast cancer based on individual patient data (JBCRG-S01) (2020) (0)
- For choosing axillary treatment, and adjuvant hormonal treatment (2016) (0)
- MO33-7 Preparedness for COVID-19 pandemic and impact on medical oncology for breast cancer (2021) (0)
- P172 Prognosis of hormone receptor positive recurrent breast cancer during endocrine therapy (2015) (0)
- Ultrasonographic imaging of invasive ductal carcinoma linked to revision of the histological classification of breast tumors (2021) (0)
- P280 Differentiation between luminal-HER2 and HER2-enriched breast cancer in clinical course (2015) (0)
- Abstract P2-15-01: A randomized, multicenter, phase II study evaluating the efficacy of interventional maintenance endocrine therapy with bevacizumab following fixed cycles of bevacizumab plus paclitaxel in advanced/metastatic ER-positive HER2-negative breast cancer: JBCRG-M04 BOOSTER trial (2020) (0)
- P20 26 MP – EFFECT OF BLEOMYCIN AND LIBLOMYCIN COMBINED WITH WHOLE BODY HYPERTHERMIA ON TUMOR AND NORMAL TISSUE IN RATS (1991) (0)
- Abstract P5-11-13: Outcomes of fulvestrant therapy among Japanese women with ER-positive HER2-positive advanced or metastatic breast cancer: A subgroup analysis of the JBCRG-C06 safari study (2020) (0)
- Abstract P5-18-11: Prognostic impact and possible pathogenesis of lymph node metastasis in ductal carcinoma in situof the breast (2019) (0)
- Abstract P1-01-05: Adjuvant S-1 plus endocrine therapy for estrogen receptor-positive, HER2-negative, primary breast cancer: updated overall survival analysis from the POTENT trial (2023) (0)
- Childbirth after perioperative systemic therapy in patients with breast cancer: a retrospective single institutional study in Japan. (2023) (0)
- 311P Pooled-analysis of prospective observational studies evaluated the effectiveness and safety of bevacizumab and paclitaxel as the first-line chemotherapy for HER2-negative metastatic breast cancer (2020) (0)
- Conserved cysteine residues in Kaposi’s sarcoma herpesvirus ORF34 are necessary for viral production and viral pre-initiation complex formation (2023) (0)
- S10-5 Team Approach to Support the Patients with Breast Cancer(ISPOG2007) (2007) (0)
- Altered lymphatic drainage patterns in re-operative sentinel lymph node biopsy for ipsilateral breast tumor recurrence (2019) (0)
- Crystal structure of Mumps virus hemagglutinin-neuraminidase bound to 3-sialyllactose (2016) (0)
- Eribulin-induced liver dysfunction as a prognostic indicator of survival of metastatic breast cancer patients: a retrospective study (2016) (0)
- Crystal structure of Mumps virus hemagglutinin-neuraminidase (2016) (0)
- Roles of HTLV-I p19 and natural antibody to HTLV-I in host immune responses. (1985) (0)
- GRHL2 motif is associated with intratumor heterogeneity of cis-regulatory elements in luminal breast cancer (2022) (0)
- Breast castleman disease (2020) (0)
- [Measles virus entry and cellular receptors]. (2007) (0)
- CLINICAL STUDY ON A MONOCLONAL ANTIBODY-SANDWICH RIA FOR SQUAMOUS CELL CARCINOMA RELATED ANTIGEN IN SERUM OF THE PAIENTS WITH ESOPHAGEAL CARCINOMA: A COMPARATIVE STUDY WITH TWO ANTIBODY METHOD@@@二抗体法とビーズ固相法との比較検討 (1987) (0)
- 163MO Randomized phase II study of eribulin-based neoadjuvant chemotherapy for triple-negative primary breast cancer patients stratified by homologous recombination deficiency status (JBCRG-22) (2020) (0)
- Murine gammaherpesvirus 68 glycoprotein 150 does not contribute to latency amplification in vivo (2012) (0)
- Factors associated with overall survival after recurrence in patients with ER-positive/HER2-negative postmenopausal breast cancer: an ad hoc analysis of the JBCRG-C06 Safari study. (2022) (0)
- Certification of Biological Character and Strategy for Treatment in Regard to the Metastasis of the Gastric Cancer (1994) (0)
- CD 46-Independent Mechanism and Syncytium Formation via a SLAM-and Supports Efficient Measles Virus Growth A Human Lung Carcinoma Cell Line (2007) (0)
- Chromatin profile-based identification of a novel ER-positive breast cancer subgroup with reduced ER-responsive element accessibility (2023) (0)
- Abstract P3-03-23: Which factor of metastatic lymph nodes–The number, tumor volume or anatomical location–Is independently prognostic in breast cancer? - A prospective cohort study using molecular whole-node analysis of all removed axillary nodes (2019) (0)
- Intratumoral heterogeneity, treatment response, and survival outcome of ER-positive HER2-positive breast cancer. (2023) (0)
- Insulin-like growth factor Ⅱmessenger RNA-binding protein-3 is an indicator of malignant phyllodes tumor of the breast (0)
- Abstract P2-03-15: Retrospective study using database for the effectiveness of medroxyprogesterone acetate in patients with ER-positive/HER2-negative postmenopausal advanced breast cancer: An additional analysis of the JBCRG-C06 Safari study (2023) (0)
- Abstract P5-08-47: Clinical outcome of pathological T1N0 breast cancer according to the hormone receptor and HER2 status and adjuvant therapy (2016) (0)
- Impact of BMI on survival and toxicity in early breast cancer: An exploratory analysis of prospective randomized phase III study N-SAS BC02 and 03. (2015) (0)
- Both type I and type III interferons are required to restrict measles virus growth in lung epithelial cells (2018) (0)
- Computational analysis of flow field characteristics of a liquid rocket unshrouded impeller (2019) (0)
- [Clinical implementation of the immunohistochemical intrinsic subtypes of breast cancer]. (2012) (0)
- Characteristics and prognosis of leptomeningeal metastasis in patients with breast cancer (2019) (0)
- Correction to: Validation of a nuclear grading system for resected stage I–IIIA, high-risk, node-negative invasive breast carcinoma in the N·SAS-BC 01 trial (2022) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Shinji Ohno?
Shinji Ohno is affiliated with the following schools:
